Clinical Trial Update: Toripalimab Plus Bevacizumab and Chemotherapy as Neoadjuvant Therapy in Advanced MSI-H or dMMR Colorectal Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating toripalimab plus bevacizumab and chemotherapy as neoadjuvant therapy in advanced MSI-H or dMMR colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Peking University | Conditions: Colorectal Carcinoma | Phase 1, Phase 2 | Status: UNKNOWN